Health security

Bavarian Nordic Announces Positive Results From Clinical Studies Of IMVAMUNE Smallpox Vaccine

The same week Bavarian Nordic A/S announced its preliminary Phase 1 results for Ebola Prime-Boost Vaccine, the company also announced results from the first of two pivotal phase 3 studies of the liquid-frozen formulation of IMVAMUNE supporting a Biologics License Application for US approval of its Smallpox vaccine. 

In addition, the company announced results from a pivotal Phase 2 study of freeze-dried IMVAMUNE smallpox vaccine supporting the clinical requirements for an Emergency Use Authorization, which would allow for stockpiling of this next-generation of the vaccine.